Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN
Posted on: 01 Nov 18

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

Cambridge, UK – 30th October 2018 - DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Broad Institute CRISPR-Cas9 technology will be combined with DefiniGEN’s best-in-class induced Pluripotent Stem Cell (iPSC) differentiation platform to generate preclinical cell models which can accelerate Type 2 diabetes, non-alcoholic steatohepatitis (NASH), and orphan liver disease drug discovery programmes.

"Through our license with Broad Institute, we are pleased to be able to enhance our customer’s research programs by offering state-of-the-art CRISPR-Cas9 gene edited disease model cell products and custom services," commented Dr Marcus Yeo CEO of DefiniGEN.

DefiniGEN will produce CRISPR-Cas9 gene edited cells, enabling customers to exploit the power of genome editing, alongside world-leading stem cell production and disease modelling capabilities.

For more information, please click here

About DefiniGEN: https://www.definigen.com

DefiniGEN was founded to commercialise OptiDIFF, a best-in-class stem cell production platform developed at the University of Cambridge, UK. The Company has world-leading expertise in the area of induced Pluripotent Stem Cell (iPSC)-derived human cell production and metabolic disease modelling. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective therapeutics. DefiniGEN builds on intellectual property and knowledge resident at the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital and has in-licensed the Yamanaka iPSC IP portfolio from iPS Academia Japan Inc.

For more information:
www.definigen.com

Editor's Details

Leigh Dilley
BioStrata Ltd
biostratamarketing.com
01223253787
ldilley@biostratamarketing.com

Last updated on: 01/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.